Provides infusion therapy and medications, with related nursing and care coordination, for patients with complex and chronic conditions at home and other nonhospital settings, working with health plans, hospitals and physicians.
10-K for FY2025, filed Feb 24, 2026
Third-party payers and patients pay for pharmaceuticals and related infusion care; the company is paid for medicines when they are delivered and for nursing when care is provided. It also earns fees from some biotech manufacturers for clinical outcomes and data services.
10-K for FY2025, filed Feb 24, 2026The Company generates most of its revenue from contracts with third-party payers, including managed care organizations, insurance…View ↗
Net Revenue. Infusion and related healthcare services revenue is reported at the estimated net realizable amounts from third-party payers…View ↗
The Company purchases pharmaceuticals and medical supplies directly through pharmaceutical manufacturers, authorized distributors and group…View ↗
$5.6B
10-K for FY2025, filed Feb 24, 2026
$5.6B ↗
Managed care organizations, insurers, employers and government programs reimburse most services; where allowed, Option Care bills patients for amounts those payers do not cover. It contracts with payers and works with hospitals, physicians and other referral sources to connect patients with care at home and other nonhospital settings.
10-K for FY2025, filed Feb 24, 2026Option Care Health contracts with managed care organizations, third-party payers, hospitals, physicians and other referral sources to…View ↗
The Company’s sales and marketing efforts focus on three primary objectives: (1) building new relationships and expanding existing…View ↗
The Company generates most of its revenue from contracts with third-party payers, including managed care organizations, insurance…View ↗
10-K for FY2025, filed Feb 24, 2026
The Company’s largest payer represented approximately 14% of its revenue for the year ended December 31, 2025. No other single payer…View ↗
Yes. It kept 4 cents of every revenue dollar as net income in FY2025 and turned 4 cents into free cash flow.
8-K, filed Apr 30, 2026
Net revenue of $5.675 billion to $5.775 billionView ↗
Growing. Revenue grew 64% in 4 years, from $3.4B in FY2021 to $5.6B in FY2025, about 13% a year.
Competes with UnitedHealth Group, CVS Health, BrightSpring Health, KabaFusion, Soleo Health, Vital Care, Accredo, CVS Caremark, Optum Rx, and Orsini
10-K for FY2025, filed Feb 24, 2026The Company competes in the large and highly fragmented home and alternative site infusion market for contracts with managed care…View ↗
Loading...